Progenics Pharmaceuticals (NASDAQ:PGNX) will be issuing its Q3 quarterly earnings data before the market opens on Thursday, November 8th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.
NASDAQ:PGNX opened at $5.30 on Wednesday. The company has a market capitalization of $446.38 million, a PE ratio of -5.89 and a beta of 2.81. Progenics Pharmaceuticals has a 1 year low of $4.68 and a 1 year high of $9.42. The company has a debt-to-equity ratio of 0.68, a current ratio of 6.34 and a quick ratio of 6.34.
PGNX has been the subject of several analyst reports. Zacks Investment Research raised Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, September 11th. BidaskClub lowered Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, September 5th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Progenics Pharmaceuticals in a research note on Wednesday, August 1st. Needham & Company LLC lowered Progenics Pharmaceuticals from a “strong-buy” rating to a “buy” rating and lowered their price objective for the company from $16.00 to $12.00 in a research note on Thursday, September 13th. Finally, ValuEngine raised Progenics Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 30th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $11.69.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://weekherald.com/2018/11/07/progenics-pharmaceuticals-pgnx-scheduled-to-post-quarterly-earnings-on-thursday.html.
Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.
Further Reading: Calculate Your Return on Investment (ROI)
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.